Tranflex

Quick links to important sections

Tranflex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tranflex

Quick Facts: Tranflex

Property Description
Active ingredient Chlormezanone
Form Tablet (Oral preparation)
Pharmacological class Central Nervous System (CNS) Depressant, Anxiolytic, Skeletal Muscle Relaxant
General purpose Relief from psychological tension and muscle spasm
Origin Synthetic compound

What Type of Medicine is Tranflex and What Does it Contain?

Tranflex is a prescription-only medication whose active constituent is the synthetic compound Chlormezanone. This substance is formally classified as both an anxiolytic and a muscle relaxant, placing it within the therapeutic class of Central Nervous System (CNS) Depressants. Chlormezanone is a non-benzodiazepine agent belonging to the chemical group of Benzoxazinone derivatives. The identity of Tranflex is rooted entirely in this single active ingredient product (monotherapy), which defines its dual effects.

What Form is Tranflex Supplied In?

The drug Tranflex is an Oral preparation, meaning its route of administration is by mouth for systemic absorption. It is typically supplied in tablet form, which is the most convenient dosage form for sustained action. The tablets incorporate the active Chlormezanone alongside standard, inactive solid pharmaceutical excipients essential for manufacturing and proper breakdown within the body. The synthetic origin of the active ingredient ensures a consistent chemical structure, critical for a centrally acting agent.

What is the General Purpose of Tranflex's Dual Action?

The general purpose of Tranflex is to modulate neural activity to relieve discomfort associated with combined physical and psychological tension states. The medicine functions by providing a mild anti-anxiety action (anxiolytic) and simultaneously reducing involuntary muscle stiffness (skeletal muscle relaxant). This dual function serves as an approach for addressing the frequent link between heightened psychological tension and persistent skeletal muscle spasm, which are both caused by central nervous system overactivity.

What side effects are possible with Tranflex?

Possible Side Effects and Safety Information

The safety profile of Chlormezanone (Tranflex's active ingredient) is officially documented by its potential for both common central nervous system effects and rare, severe adverse reactions. As a CNS depressant, the most frequently reported adverse reactions affect the Nervous System and are generally classified as common, including sedation, somnolence (drowsiness), and dizziness.


Serious Adverse Reactions and Regulatory Status

Official regulatory sources highlight the risk of severe, life-threatening reactions that led to significant market restrictions. These rare but serious adverse events primarily involve the Skin and Subcutaneous Tissue Disorders and the Hepatobiliary Disorders.

System-Organ Class Serious Adverse Reaction (Documented Risk)
Skin and Subcutaneous Tissue Disorders Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS)
Hepatobiliary Disorders Severe liver disorders and hepatotoxicity (liver damage/failure)

The drug's unfavorable benefit/risk profile, based largely on the potential for these severe cutaneous reactions, resulted in the withdrawal of marketing authorizations by government health authorities globally.


Population and Duration-Related Safety Patterns

Population-specific safety notes indicate that psychiatric effects like confusion and mood swings are more likely to occur in older adults. Furthermore, the safety profile documents patterns related to treatment duration: long-term use carries a risk of developing dependency, and abrupt discontinuation may precipitate serious withdrawal symptoms (e.g., seizures, rebound anxiety). All listed reactions and safety constraints are consistent with official regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Tranflex overdose focuses strictly on the manifestations and required emergency response for this central nervous system depressant. Initial documented signs of overdose include escalating drowsiness, pronounced physical weakness, and symptoms such as nausea and altered consciousness.

The primary life-threatening risks are associated with severe CNS depression, which can progress from profound sedation to coma. Officially documented severe outcomes include respiratory depression, a critical decrease in breathing function, and hypotension (dangerously low blood pressure). Additionally, severe end-organ damage, specifically hepatocellular damage (liver damage) and potential renal tubular necrosis (kidney damage), are documented complications requiring attention.

Immediate medical assistance is required for all suspected overdose scenarios. Regulatory statements mandate that urgent help must be sought if signs of severe toxicity—such as difficulty breathing or loss of consciousness—are observed. Since no specific antidote is known, the required management strategy is confined to symptomatic and supportive treatment under close professional monitoring. This includes close observation of vital signs and continuous liver function monitoring due to the documented risk of severe organ toxicity.

Therapeutic Uses of Tranflex

What Tranflex Treats: Main Uses and Benefits

Tranflex is commonly used in situations involving certain distressing symptoms across related therapeutic domains. The core benefit of the medication provides support that helps ease the overall symptom burden in patients experiencing symptoms related to physical discomfort linked to stress.

Its primary therapeutic indication involves muscle contracture. The medication is generally applied in contexts marked by increased discomfort or tension, relevant for managing symptoms that interfere with daily comfort, offering symptomatic relief that helps patients cope more steadily.

The primary symptomatic applications may assist with addressing involuntary skeletal muscle spasms, muscle tightness and hypertonicity, and the accompanying psychological tension. It is used in clinical settings that involve acute or disruptive symptom patterns, such as providing short-term symptomatic assistance during episodes of sudden discomfort that follow strains, sprains, or minor physical injuries. This dual action may be part of symptomatic management relevant for managing symptoms that interfere with daily comfort.

Quick Fact: Relief for Dual Discomfort
Primary Physical Target Involuntary muscle spasms and associated stiffness
Associated Symptom Psychological tension and inner unrest
Benefit Focus Contributes to easing the overall symptom load and supporting coping ability
Scenario Relevance Conditions associated with acute or disruptive episodes or stress-induced tension

Regulatory References

  1. European Commission's Union Register of medicinal products

Eligibility and Restrictions for Use

Tranflex (Chlormezanone) has a definitive eligibility profile rooted in global regulatory actions. The medication was discontinued worldwide by its manufacturer due to confirmed risks of rare but life-threatening cutaneous reactions, meaning the population eligible for current use is officially none.


Contraindicated Populations

Prior to its withdrawal, official labeling defined absolute prohibitions for use, stating the medicine was contraindicated in:

  • Individuals with known hypersensitivity to chlormezanone or any component.
  • Patients with active hepatic disease (active liver disease).

Populations Not Recommended or Restricted

Use was generally not recommended or required strict caution for the following groups:

  • Pediatric population (safety and efficacy are not established).
  • Pregnant and breastfeeding women (safety is not established).
  • Older adults (caution required due to risk of age-related impaired liver function).
  • Patients with specific comorbidities, including Glaucoma, Depression, and severe hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tranflex (Chlormezanone) is classified as a Central Nervous System (CNS) Depressant, which dictates the primary patterns of documented interactions found in official regulatory labeling. These interactions are categorized by their effects on the body's chemistry (pharmacokinetic) and the drug's activity (pharmacodynamic).

Pharmacodynamic Interactions: The most significant interaction involves additive CNS depression. Co-administration with other medicines that slow CNS activity, such as sedatives, hypnotics, opioid analgesics, certain antihistamines, and other muscle relaxants, may result in enhanced central depressant effects. This is a clinically significant regulatory caution for all agents in this pharmacological class.

Pharmacokinetic Interactions: The drug's clearance is subject to modification by agents affecting its liver metabolism. Substances classified as hepatic enzyme inhibitors may increase the drug's plasma concentration and exposure. Conversely, hepatic enzyme inducers may decrease the active ingredient's exposure and concentration.

Substance and Population Restrictions: The official profile explicitly documents restrictions concerning substances such as alcohol, as consumption is associated with a specific enhancement of CNS depressant effects. Furthermore, regulatory cautions note that interaction risks and severity may be elevated in patients with hepatic impairment due to the potential for altered clearance.

Mechanism of Action

How Tranflex Works

Tranflex acts via targeted modulation of specific receptor- and enzyme-mediated signaling pathways. The compound engages regulatory mechanisms to modify activity within systems exhibiting heightened or dysregulated physiological responses, resulting in altered functional states.


Modulation of Specific Receptor Signaling

This domain involves Tranflex initiating or suppressing signaling sequences at specific cell-surface receptors. Modification of these early molecular steps influences systemic physiological consequences, reducing the magnitude of specific physiological responses and modifying pathway dynamics.


Regulation of Key Enzyme Activity

Tranflex also acts to influence mechanisms that regulate overactive processes by altering the function of critical enzymes within the cascade. This modification reduces the consequence of excessive mediator activity, resulting in an altered or attenuated state within the targeted physiological pathways.

Dosage and Administration Information

Tranflex is an antifibrinolytic agent. The proper use of the medication depends significantly on the specific formulation (tablet, injection) and the condition being treated.

Oral Tablet Administration

For oral use, such as for the management of cyclic heavy menstrual bleeding, the tablets are typically administered for a maximum of five days during monthly menstruation. The tablets must be swallowed whole and should not be chewed or broken apart. Tranflex tablets may be taken with or without food, but maintaining a consistent regimen regarding food intake is recommended to minimize variability in drug exposure.

  • Recommended Dose (Normal Renal Function): 1300 mg taken by mouth three times daily (3900 mg/day).

Dosage Adjustments

Patients with renal impairment (impaired kidney function) require a reduced dosage as Tranflex is primarily eliminated by the kidneys. A healthcare provider determines the appropriate lower dosage based on serum creatinine concentration.

Injection Administration

When administered as an intravenous injection, such as for short-term use in patients with hemophilia following tooth extraction, the drug is infused into the vein. The infusion must be performed slowly—no faster than 1 mL/minute—to mitigate the risk of developing hypotension (low blood pressure). The intravenous dosage is weight-based, typically 10 mg/kg actual body weight, administered before the procedure. Subsequent doses may be given three to four times daily for several days as directed by a healthcare professional.

Recent Clinical Evidence

Tranflex: Recent Clinical Evidence

Clinical research has focused on the efficacy and safety profile of Tranflex for its approved indication, which is the management of partial-onset seizures in adults with epilepsy. Studies often evaluate Tranflex both as a monotherapy (used alone) and as adjunctive therapy (used in combination with other anti-seizure medications).


Efficacy Data

Phase 3 trials have been conducted to assess the effect of Tranflex in reducing seizure frequency. In placebo-controlled, double-blind trials, patients receiving Tranflex as an add-on therapy showed a statistically significant reduction in median weekly seizure frequency compared to those receiving a placebo. The proportion of patients who experienced a 50% or greater reduction in seizure frequency was observed to be higher in the group treated with Tranflex than in the placebo group.

Safety and Tolerability

Tranflex is generally considered to be associated with a distinctive side-effect profile compared to older agents. The most commonly reported adverse events in clinical trials often include central nervous system (CNS)-related effects such as dizziness, somnolence (drowsiness), and fatigue. Other frequently noted side effects may involve behavioral or psychiatric symptoms, including irritability, nervousness, or mood changes. The frequency of these adverse events may be dose-dependent.


Summary of Trial Outcomes

Outcome Measure Finding (vs. Placebo in Adjunctive Trials)
Reduction in Seizure Frequency Statistically significant reduction observed
Proportion of Responders (>50% reduction) Higher proportion of responders noted
Most Common Adverse Events Dizziness, somnolence, fatigue

Long-term follow-up studies suggest that the safety profile is generally maintained with extended use, though individual response and tolerability may vary among patients. Discussions with a healthcare provider can clarify the relevance of this research to individual circumstances.

Frequently Asked Questions (FAQ)

Common questions about Tranflex (FAQ)

Q: How quickly does Tranflex start working?

A: Official product information, typically found in the clinical pharmacology section, describes the time it takes for the active ingredient to be absorbed and reach its maximum concentration in the blood. This pharmacokinetic information relates to the drug's activity profile.


Q: Why do some people say Tranflex makes them sleepy?

A: Regulatory documents classify Tranflex as a Central Nervous System (CNS) Depressant. This means the drug works by slowing down activity in the brain and central nervous system. This known effect results in commonly reported side effects such as drowsiness (somnolence) and dizziness.


Q: Does Tranflex interact with blood pressure medicine?

A: The official labeling warns of potential interactions with medicines that either slow down the central nervous system (pharmacodynamic interactions) or affect how the body metabolizes the drug in the liver (pharmacokinetic interactions). This is why the regulatory profile advises caution when reviewing all medications a patient is taking.


Q: Can I take vitamins or supplements while using Tranflex?

A: The drug's official safety profile notes potential interactions with substances that affect certain drug-metabolizing enzymes in the liver. Since some vitamins, supplements, or herbal products can influence these enzymes, regulatory documents emphasize the importance of ensuring a healthcare provider is aware of all products a patient is using.


Q: What happens if I forget to take a dose of Tranflex?

A: Official instructions for missed doses provide general regulatory principles for managing the situation. Patients are explicitly cautioned against taking a double dose to compensate for a missed one.


Q: Is Tranflex suitable for older adults (seniors)?

A: Official labeling advises that caution is required for use in older adults. This is due to the potential for age-related changes in liver function and a higher likelihood of experiencing certain effects, such as confusion and changes in mood.


Q: What should I do if a side effect of Tranflex doesn't go away?

A: The official safety profile outlines rare but serious adverse reactions (like severe liver disorders or severe skin reactions such as SJS or TEN) that require immediate medical attention. For other side effects, the patient counseling section describes monitoring for side effects and seeking clarification from a healthcare provider for any concerns.


Q: How long does the effect of Tranflex last?

A: The duration of the drug's clinical effect is related to its half-life, which is the time it takes for half of the drug to be eliminated from the body. This factor is used to determine the necessary interval between administrations to maintain consistent levels in the body.


Q: What happens when I stop taking Tranflex?

A: Abrupt discontinuation, especially after long-term use, is associated with the risk of precipitating serious withdrawal symptoms, which may include seizures and rebound anxiety. The regulatory profile indicates that a gradual dosage reduction is generally utilized to mitigate withdrawal symptoms.


Q: Can people with kidney conditions take Tranflex?

A: Official regulatory information indicates that patients with renal impairment (impaired kidney function) require a reduced dosage because the drug is primarily processed and eliminated from the body by the kidneys.


Q: How does Tranflex affect blood sugar levels?

A: Official safety documents report that effects on blood sugar levels, including both increases (hyperglycemia) and decreases (hypoglycemia), have been documented as adverse reactions associated with the drug.


Q: Can Tranflex be crushed or split?

A: Official administration instructions state that the tablets must be swallowed whole and should not be chewed or broken apart. This instruction is necessary for the medicine to be absorbed as intended.


Q: Where can I find the official patient information leaflet for Tranflex?

A: The FDA and other health authorities require that a complete, patient-friendly document, often known as the Medication Guide or Patient Information Leaflet, be made available with the prescription. These official documents are also accessible through government online databases, such as DailyMed.


Q: What are the components of Tranflex tablets?

A: The tablets contain the active ingredient Chlormezanone and a list of inactive solid pharmaceutical excipients (non-active components), which are necessary for the tablet's manufacturing, stability, and proper breakdown in the body, and are detailed in the official product label.


Q: Does the evidence for Tranflex come from human studies only?

A: Regulatory evidence is drawn from multiple sources. It includes human clinical trials (efficacy and safety data) as well as non-clinical data, which provides important information from animal and in vitro studies regarding toxicology and pharmacology.


Q: What is the difference between the brand name and generic Tranflex?

A: Regulatory standards define a generic version as containing the identical active ingredient (Chlormezanone) as the brand-name product. It must also demonstrate bioequivalence, meaning it meets regulatory standards for working in the same manner as the brand-name product.


Q: Can Tranflex be taken at night?

A: The administration regimen is typically divided into two or three doses per day, with the final dose potentially taken in the evening. Because the drug may cause drowsiness, official information suggests discussing the optimal timing of administration with a healthcare provider.


Q: Is Tranflex safe for long-term use?

A: Due to the risk of rare but severe adverse reactions, including life-threatening skin and liver disorders, the drug was withdrawn globally by health authorities. Furthermore, the official label noted that long-term use carried a risk of developing dependency.


Q: Is it true that Tranflex can cause stomach issues?

A: Official adverse event reporting documents include the possibility of gastrointestinal disturbances, such as nausea and abdominal pain, as side effects associated with the medication.


Q: Can Tranflex be used by teenagers?

A: Regulatory information states that the safety and efficacy have not been established for the pediatric population, which includes teenagers. Use was generally not recommended for this age group prior to the drug's withdrawal.


Q: Are there any food restrictions while taking Tranflex?

A: Official instructions state the tablets may be taken with or without food. There are no specific food restrictions mentioned in the regulatory profile beyond the guidance on taking the dose with or without food.


Q: Is Tranflex a controlled substance?

A: The drug's classification as a Central Nervous System (CNS) Depressant and its potential for dependency places it under specific government regulation. Official sources specify whether the medication is classified as a scheduled controlled substance.


Q: Can I take another medication for pain relief along with Tranflex?

A: The regulatory profile requires caution when combining Tranflex with any other centrally acting medicine. Co-administration with certain other pain medications may result in additive central nervous system depressant effects.


Q: Are there any warning signs I should look for when starting Tranflex?

A: Official warnings advise patients to monitor for early indicators of serious adverse reactions. These include signs of severe skin disorders (such as rash or swelling) and signs of liver disorder (such as unexplained jaundice or dark urine).


Q: Is it normal to feel a change in mood while on Tranflex?

A: The safety profile documents that psychiatric or behavioral effects, including irritability, nervousness, and mood changes, have been reported as adverse events in clinical trials and are listed as possible effects.


Q: How often are the safety warnings for Tranflex updated?

A: Safety warnings and official drug labeling are periodically reviewed and updated by regulatory authorities. This process happens in response to new information gathered from post-marketing surveillance reports or the results of ongoing research studies.


Q: Is Tranflex related to any other commonly known drugs?

A: Tranflex is a Benzoxazinone derivative and is classified as a non-benzodiazepine agent. It belongs to the broader therapeutic class of Central Nervous System (CNS) Depressants, which links it to other medicines that slow brain activity.


Q: Is Tranflex considered a new or old drug?

A: The drug is considered an older synthetic compound that was introduced decades ago. It was subsequently withdrawn globally by health authorities due to confirmed safety risks, which highlights its historical nature.


Q: Are there different strengths of Tranflex available?

A: The official labeling specifies the available dosage forms (such as tablet or injection) and the precise strength of the active ingredient (Chlormezanone) contained in each product.


Q: Why is Tranflex sometimes prescribed for a short time only?

A: Regulatory caution is advised against long-term use due to the risk of developing dependency and the potential for severe withdrawal symptoms upon discontinuation. The regulatory profile indicates this is why it is typically intended for short-term therapeutic use.


Q: Does Tranflex interact with common anti-anxiety medications?

A: Yes, co-administration with other anxiolytic (anti-anxiety) medications may result in additive central nervous system depressant effects. This is a significant regulatory caution because both classes of drugs affect the central nervous system.

How should Tranflex be stored and disposed of?

The official storage and disposal guidelines for Tranflex (Chlormezanone tablets) are set by regulatory bodies to maintain the product's integrity and ensure public safety.

Storage Requirements

Tranflex must be stored at Controlled Room Temperature, which generally means between 20 C and 25 C (68 F and 77 F). The product must be protected from light, moisture, and excessive heat. It is critical to keep the tablets in a tightly closed container and out of the sight and reach of children to prevent accidental ingestion. The tablets must not be frozen.

Disposal Instructions

Unused or expired Tranflex must be disposed of according to official protocols. The preferred method is to use a community drug take-back program. If one is unavailable, the product should be disposed of in the household trash by mixing it with an unappealing substance, placing it in a sealed container, and discarding it. Medicine must not be flushed down the toilet or poured down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tranflex found in:

A-Z Index: